Abstracts Archive - Page 37 of 2607 - ACR Meeting Abstracts

Abstract Number: 2281 • ACR Convergence 2025
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Louis Bessette¹, Andrew Chow², Raman Rai³, Hugues Allard-Chamard⁴, Pauline Boulos⁵, Guylaine Roy⁶ and Dalinda Liazoghli⁶, ¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ²Credit Valley Rheumatology, Mississauga, McMaster University, Hamilton, University of Toronto, Toronto, ON, Canada, ³Drs. Rai & Sekhon Medicine Professional Corporation, Brampton, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶AbbVie Corporation, Saint-Laurent, QC, Canada
Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)-inhibitor proven effective and well-tolerated in patients with rheumatoid arthritis (RA) in 6 randomized clinical trials.…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 0312 • ACR Convergence 2025
Efficacy and Safety of Tocilizumab in Children with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis
Kainat Jahangir¹, Meer Murtaza², Rida Ul Jannat³, Muhammad Arham⁴, Najam Gohar⁵, Faseeh Haider⁶, Rohma Ahmed⁷, FNU Raja⁸, Rabie Habib⁹, Mahnoor Umar¹⁰, Hira Saleem¹¹, Faizan Ahmed¹², Tehmasp Mirza¹³, Momina Siddiqui¹⁴, Muhammad Umer¹⁵, Haziq Ahmed¹⁶, Maryam Anwar¹⁷, Rehab Bint e Tahir¹⁸, Yusra Junaid¹⁹ and Ramsha Ali²⁰, ¹Dow Medical College, Karachi, Pakistan, ²Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, ³Wake Forest University, Winston Salem North Carolina, Winston-Salem, NC, ⁴Sheikh Zayed Medical College, Lahore, Pakistan, ⁵Ameer Ud Din Medical College, Sialkot, Pakistan, ⁶Allama Iqbal Medical college, Lahore, Punjab, Pakistan, ⁷Fatima Jinnah Medical University, Lahore, Pakistan, ⁸Federal Medical and Dental College, Islamabad, Pakistan, ⁹Baylor College of Medicine, Texas, Pakistan, ¹⁰Nassau University Medical Center, New York, ¹¹Houston Methodist Hospital, Texas, ¹²Corewell health, dearborn, MI, ¹³Shalamar Medical and Dental College, Lahore, Pakistan, ¹⁴Rawalpindi Medical Univeristy, Rawalpindi, Punjab, Pakistan, ¹⁵King Edward Medical College, Lahore, Pakistan, ¹⁶Sheikh Khalifa bin zayed Alnahyan Medical College, Lahore, Punjab, Pakistan, ¹⁷Baqai Medical University, Karachi, Pakistan, ¹⁸-, lahore, ¹⁹Dow University of health and sciences, karachi, Pakistan, ²⁰Peoples University of Medical and Health Sciences SBA, NawabShah, Pakistan
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses various chronic inflammatory conditions in children that lead to joint discomfort and potential disability. Tocilizumab, an antibody targeting interleukin-6,…
Abstract Number: 0245 • ACR Convergence 2025
Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
cristiana Sieiro¹, Sarah Dyball², Ellen Bruce³, Ben Parker⁴ and Ian Bruce⁵, ¹Univrsity of Manchester, Manchester, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³Manchester University NHS FT, The Kellgren Centre of Rheumatology, Manchester, United Kingdom, Manchester, ⁴NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom, ⁵Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs), including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren’s disease (SjD), are associated with an increased risk of cardiovascular…
Abstract Number: 0280 • ACR Convergence 2025
Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
Suchada Kaewin¹, Cecilia Leijding², Kristofer Andreasson², Helene Alexanderson³, Stefano Gastaldello¹, Ingrid Lundberg² and Daniel C. Andersson², ¹Karolinska Institutet, inst fysiologi och farmakologi, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Dermatomyositis (DM) is a major subtype of idiopathic inflammatory myopathies (IIMs) and characterized by muscle weakness, systemic inflammation and cutaneous lesions. Expression of type…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
Abstract Number: 0059 • ACR Convergence 2025
Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
Ryan D. Stultz¹, Payton Hermanson², Noelle Mullin³, Simeon Ramsey³ and Christian Lood², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²University of Washington, Seattle, WA, ³Pfizer Inc., Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that disproportionately affects females over males (3:1). Although sex-based immune differences have been documented, particularly…
Abstract Number: 0412 • ACR Convergence 2025
The Association of Obesity with Juvenile Spondyloarthritis
Katelyn Baggett¹, Timothy Brandon² and Pamela Weiss³, ¹Johns Hopkins University, Newtown Square, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Childhood obesity is a global public health concern that impacts the health and wellbeing of all children and particularly negatively affects children living with…
Abstract Number: 0021 • ACR Convergence 2025
DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies
Antonio Julià¹, Yolanda Guillén², Paloma Vela Casasempere³, Antonio Fernández Nebro⁴, Carlos Marras⁵, Santos Castañeda⁶, Jaime Calvo Alén⁷, Jesús Tornero Molina⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, Jose M. Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda Fernández De pierola¹⁴, Valle García Sánchez¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Laura Jiménez Gracia¹⁸, Pere Santamaria¹⁹, Edgar Angelats²⁰, Richard Myers²¹, Sergio H. Martínez Mateu², Juan Ángel Patiño Galindo², Ernest Choy²² and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, ⁸Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ¹¹Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, ¹⁶Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, ¹⁷University of Verona, Dermatology, Verona, Spain, ¹⁸Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, ¹⁹Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, ²⁰Hospital Clínic-IDIBAPS, Barcelona, Spain, ²¹HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
Abstract Number: 0153 • ACR Convergence 2025
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Isabel Castrejón Fernández¹, Lucia Otero², Antonio Mera-Valera³, Alicia Garcia⁴, Silvia Gomez-Sabater⁵, Raquel Martín-Domenech⁶, Jose Alvaro-Gracia⁷, Juan Camilo Sarmiento-Monroy⁸, Beatriz Ventosa² and Fernando Sánchez-Alonso⁹, ¹Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³H. Clínico Universitario de Santiago, Santiago de Compostela, ⁴Rheumatologist, La Laguna, Spain, ⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁶H. Universitario de Elda, Elda, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
Abstract Number: 0277 • ACR Convergence 2025
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Vaibhav Mundra¹, Cunjing Yu², Roland Morley¹, Yuan Yuan³, Yifan Qin³, Jingjing Schneider¹, Shengnan Chen³, Zhenyuan Zhou³ and Zhen Yao², ¹BeOne Medicines USA, Inc., San Carlos, CA, ²BeOne Medicines (Beijing) Co, Ltd., Beijing, China (People's Republic), ³BeOne Medicines (Shanghai) Co, Ltd., Shanghai, China (People's Republic)
Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…
Abstract Number: 0295 • ACR Convergence 2025
Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Manali Sarkar¹, Meera Shah², Vincenzo Venerito³, Vikas Agarwal⁴ and Latika Gupta⁵, ¹Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ²Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Fatigue significantly impacts quality of life in idiopathic inflammatory myopathies (IIM) but remains poorly understood. This study aimed to identify the key determinants of…
Abstract Number: 0327 • ACR Convergence 2025
Structural Severity Assessment of Hand Osteoarthritis Using Radiomic Analysis: Correlation with the Kellgren-Lawrence Score – Results from the DIGICOD Cohort
Laetitia Perronne¹, SELLAM JEREMIE², Antoine Decoux³, Loïc Duron⁴, Constance de Margerie⁵, Maxime Dougados⁶, Simo Saarakala⁷, Emmanuel Maheu⁸, Michel Crema⁸, Anne Miquel⁸, Francis BERENBAUM⁹, Armelle Arnoux³, Jean Denis Laredo¹⁰ and Laure Fournier³, ¹Northwestern University, Chicago, IL, ²Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ³Université paris Cité, Paris, France, ⁴Hôpital Fondation Adolphe de Rothschild, Paris, France, ⁵Hôpital Saint Louis, Paris, France, ⁶Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁷University of Oulu, Oulu, Finland, ⁸Hôpital Saint Antoine, Paris, France, ⁹Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ¹⁰Hôpital Lariboisière, Paris, France
Background/Purpose: Radiomics involves the high-throughput extraction of quantitative data from medical imaging. This study aimed to develop a radiomic analysis pipeline applied to hand radiographs…
Abstract Number: 0300 • ACR Convergence 2025
Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
Reena Yaman¹, Archit Srivastava², Alejandro Arango Martinez³, Caroyln Harvey⁴, Ronald Butendieck⁵, Vikas Majithia⁶ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Universidad Pontificia Bolivariana, Medellín, Colombia, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic Florida, Jacksonville, ⁶Mayo Clinic Hospital, Jacksonville, FL
Background/Purpose: Anti-synthetase syndrome (ASyS) is a rare, heterogeneous inflammatory myopathy characterized by presence of anti-aminoacyl transfer RNA synthetase autoantibodies with multisystem disease manifestations including myositis,…
Abstract Number: 0342 • ACR Convergence 2025
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Edgar Wiebe¹, Benjamin Kuntz², Angela Galindo Santos³, Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche², Andriko Palmowski², Gerhard Krönke⁴, Ralf Schmidmaier⁵, Kay Raum³ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].